Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

NCT05143970 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT05143970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05143970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Lead sponsor
Institut Paoli-Calmettes
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 21, 2022
Completion date
March 31, 2027
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, endometrial cancer, metastatic breast cancer, metastatic cancer, metastatic gastric cancer, metastatic lung cancer, metastatic ovary cancer, metastatic pancreatic cancer, oesophageal cancer